


**REMARKS**

By the foregoing amendment to the specification, the applicants have provided a statement of related applications at page 1 of the specification, and amended the specification to remove inadvertent references to h2520-109. In addition, the applicants have corrected obvious typographical errors.

By the foregoing amendment to the claims, the applicants have amended claims 1-3 and 60 to remove reference to SEQ ID NO: 1, such that the amended claims are drawn to a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, such as a polynucleotide comprising the sequence of SEQ ID NO: 3, and have canceled claims 9, 12-45, 49-58, and 65-66 without prejudice to the applicants' right to pursue original claims at a later date. The claims pending upon entry of the instant amendment correspond to the subject matter of the claims of Group II as identified in the office action mailed January 31, 2002 in parent patent application, U.S. Serial No. 09/724,126. No new matter has been added. Claims 1-8, 10-11, 46-48, and 59-64 will be pending upon entry of the instant amendment.

Dated: January 15, 2004

Respectfully submitted,

By   
Lynn L. Janulis, Ph.D.

Registration No.: 53,066  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Agent for Applicants